Core Lab (CLB) Q1 2026 Earnings Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy CLB?
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLB
Wall Street analysts forecast CLB stock price to fall
1 Analyst Rating
0 Buy
0 Hold
1 Sell
Moderate Sell
Current: 13.670
Low
11.50
Averages
11.50
High
11.50
Current: 13.670
Low
11.50
Averages
11.50
High
11.50
About CLB
Core Laboratories Inc. is a provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry. The Company helps to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. It makes measurements of reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. It assists clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Its segments include Reservoir Description, which provides laboratory-based analytical and field services to characterize the properties of crude oil and crude oil-derived products for the oil and gas industry, and Production Enhancement segment, which provides integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Core Laboratories Shares Drop 7.4% After Disappointing Q1 2026 Results
- Significant Earnings Decline: Core Laboratories reported Q1 earnings per share of $0.06, a 76.92% miss from the expected $0.26, indicating a substantial drop in profitability that could undermine investor confidence.
- Revenue Continues to Fall: The company's revenue for the quarter was $121.8 million, reflecting a 12% sequential decline and a 1% year-over-year decrease, suggesting weak market demand and operational challenges that may lead to downward revisions in future earnings expectations.
- External Factors Impacting Performance: Severe cold weather in North America and a storm in the Mediterranean disrupted client activities and temporarily closed manufacturing facilities, exacerbating revenue and profit margin pressures, highlighting the company's vulnerability to natural disasters.
- Increased Stock Volatility: Core Laboratories has experienced 25 moves greater than 5% over the past year, and while the current stock drop is significant, the market's perception of its long-term outlook may not fundamentally change, prompting investors to carefully assess buying opportunities.
See More
Core Laboratories Q1 Results Exceed Expectations Despite Sales Decline
- Performance Overview: Core Laboratories reported Q1 CY2026 revenue of $121.8 million, slightly exceeding analyst expectations of $121 million, but reflecting a 1.4% year-on-year decline, indicating challenges in the market.
- Profit Decline: The adjusted EPS of $0.06 fell significantly short of the $0.11 expected by analysts, representing a 45.5% miss, which highlights the pressure and rising costs faced by the company in its operations.
- Market Environment Impact: Disruptions from the Middle East conflict and severe weather in North America and Europe led to project delays and reduced client activity, particularly affecting the Reservoir Description segment, with the CEO noting a situation of “all costs and no revenue.”
- Future Outlook: Despite ongoing supply chain volatility and rising raw material costs, management anticipates a gradual recovery in client activity as geopolitical conditions stabilize, driving increased demand for reservoir diagnostics and production optimization technologies.
See More
Core Laboratories Q1 2026 Earnings Call Insights
- Revenue Decline: Core Laboratories reported Q1 revenue of $121.8 million, reflecting a 12% decrease from the previous quarter and a 1% year-over-year decline, indicating significant business disruption due to the Middle East conflict, prompting a downward revision of the 2026 Q1 revenue and earnings forecast.
- Shareholder Returns: Despite challenges, the company returned cash to shareholders through quarterly dividends and repurchased over 51,000 shares valued at $900,000, demonstrating a continued commitment to shareholder interests amid operational difficulties.
- Future Outlook: Management projects Q2 2026 revenue to range between $123 million and $131 million, maintaining a cautiously optimistic view on gradual operational improvement despite geopolitical uncertainties impacting forecasting accuracy.
- Operational Risks: Executives highlighted that the volatility and unpredictability of the conflict will affect operations, particularly regarding rising raw material costs and supply chain disruptions, which could lead to demand uncertainties and operational inefficiencies.
See More
Core Lab (CLB) Q1 2026 Earnings Transcript
See More
Core Laboratories Declares Quarterly Dividend of $0.01
- Quarterly Dividend Declaration: Core Laboratories has declared a quarterly dividend of $0.01 per share, consistent with previous distributions, indicating the company's stability in the current economic climate.
- Dividend Yield: The forward yield stands at 0.23%, which, while relatively low, still provides some cash return to investors, reflecting the company's ongoing commitment to its shareholders.
- Payment Schedule: The dividend will be payable on June 1, with a record date of May 11 and an ex-dividend date also on May 11, ensuring shareholders receive their returns in a timely manner.
- Market Reaction: Despite the unchanged dividend, market sentiment towards Core Laboratories remains cautious, particularly following the downward revision of Q1 guidance due to the impact of the Middle East conflict, which may affect future dividend policies.
See More
Core Laboratories Reports Q1 Earnings Miss
- Disappointing Performance: Core Laboratories reported a non-GAAP EPS of $0.06 for Q1, missing expectations by $0.05, indicating ongoing pressure on profitability that may undermine investor confidence.
- Revenue Decline: The company's revenue for Q1 was $121.8 million, down 1.4% year-over-year and missing expectations by $3.13 million, reflecting challenges from weak market demand and increased competition.
- Margin Concerns: Despite the revenue drop, the company's profit margins remain too small, leading analysts to suggest that this could dampen investor excitement about future growth, potentially impacting stock performance.
- Guidance Revision: Core Laboratories has cut its Q1 guidance, citing the impact of the Middle East war, indicating that external factors are negatively affecting operations and may heighten market concerns regarding future performance.
See More
Core Laboratories Shares Drop 7.4% After Disappointing Q1 2026 Results
- Significant Earnings Decline: Core Laboratories reported Q1 earnings per share of $0.06, a 76.92% miss from the expected $0.26, indicating a substantial drop in profitability that could undermine investor confidence.
- Revenue Continues to Fall: The company's revenue for the quarter was $121.8 million, reflecting a 12% sequential decline and a 1% year-over-year decrease, suggesting weak market demand and operational challenges that may lead to downward revisions in future earnings expectations.
- External Factors Impacting Performance: Severe cold weather in North America and a storm in the Mediterranean disrupted client activities and temporarily closed manufacturing facilities, exacerbating revenue and profit margin pressures, highlighting the company's vulnerability to natural disasters.
- Increased Stock Volatility: Core Laboratories has experienced 25 moves greater than 5% over the past year, and while the current stock drop is significant, the market's perception of its long-term outlook may not fundamentally change, prompting investors to carefully assess buying opportunities.
See More
Core Laboratories Q1 Results Exceed Expectations Despite Sales Decline
- Performance Overview: Core Laboratories reported Q1 CY2026 revenue of $121.8 million, slightly exceeding analyst expectations of $121 million, but reflecting a 1.4% year-on-year decline, indicating challenges in the market.
- Profit Decline: The adjusted EPS of $0.06 fell significantly short of the $0.11 expected by analysts, representing a 45.5% miss, which highlights the pressure and rising costs faced by the company in its operations.
- Market Environment Impact: Disruptions from the Middle East conflict and severe weather in North America and Europe led to project delays and reduced client activity, particularly affecting the Reservoir Description segment, with the CEO noting a situation of “all costs and no revenue.”
- Future Outlook: Despite ongoing supply chain volatility and rising raw material costs, management anticipates a gradual recovery in client activity as geopolitical conditions stabilize, driving increased demand for reservoir diagnostics and production optimization technologies.
See More
Core Laboratories Q1 2026 Earnings Call Insights
- Revenue Decline: Core Laboratories reported Q1 revenue of $121.8 million, reflecting a 12% decrease from the previous quarter and a 1% year-over-year decline, indicating significant business disruption due to the Middle East conflict, prompting a downward revision of the 2026 Q1 revenue and earnings forecast.
- Shareholder Returns: Despite challenges, the company returned cash to shareholders through quarterly dividends and repurchased over 51,000 shares valued at $900,000, demonstrating a continued commitment to shareholder interests amid operational difficulties.
- Future Outlook: Management projects Q2 2026 revenue to range between $123 million and $131 million, maintaining a cautiously optimistic view on gradual operational improvement despite geopolitical uncertainties impacting forecasting accuracy.
- Operational Risks: Executives highlighted that the volatility and unpredictability of the conflict will affect operations, particularly regarding rising raw material costs and supply chain disruptions, which could lead to demand uncertainties and operational inefficiencies.
See More
Core Lab (CLB) Q1 2026 Earnings Transcript
See More
Core Laboratories Declares Quarterly Dividend of $0.01
- Quarterly Dividend Declaration: Core Laboratories has declared a quarterly dividend of $0.01 per share, consistent with previous distributions, indicating the company's stability in the current economic climate.
- Dividend Yield: The forward yield stands at 0.23%, which, while relatively low, still provides some cash return to investors, reflecting the company's ongoing commitment to its shareholders.
- Payment Schedule: The dividend will be payable on June 1, with a record date of May 11 and an ex-dividend date also on May 11, ensuring shareholders receive their returns in a timely manner.
- Market Reaction: Despite the unchanged dividend, market sentiment towards Core Laboratories remains cautious, particularly following the downward revision of Q1 guidance due to the impact of the Middle East conflict, which may affect future dividend policies.
See More
Core Laboratories Reports Q1 Earnings Miss
- Disappointing Performance: Core Laboratories reported a non-GAAP EPS of $0.06 for Q1, missing expectations by $0.05, indicating ongoing pressure on profitability that may undermine investor confidence.
- Revenue Decline: The company's revenue for Q1 was $121.8 million, down 1.4% year-over-year and missing expectations by $3.13 million, reflecting challenges from weak market demand and increased competition.
- Margin Concerns: Despite the revenue drop, the company's profit margins remain too small, leading analysts to suggest that this could dampen investor excitement about future growth, potentially impacting stock performance.
- Guidance Revision: Core Laboratories has cut its Q1 guidance, citing the impact of the Middle East war, indicating that external factors are negatively affecting operations and may heighten market concerns regarding future performance.
See More
